RecruitingPHASE1, PHASE2NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Tulmimetostat(drug)
- Enrollment
- 275 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2030
Study locations (30)
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- South Texas Accelerated Research Therapeutics (Start) - Midwest Location, Grand Rapids, Michigan, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
- Weill Medical College of Cornell University, New York, New York, United States
- Montefiore Einstein Center for Cancer Care, The Bronx, New York, United States
- University of Cincinnati Medical Center, Cincinnati, Ohio, United States
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
- University of Virginia Health System, Charlottesville, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04104776 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerElizabeth K. Lee MD
- ACTIVE NOT RECRUITINGPHASE2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)